Provided by Tiger Trade Technology Pte. Ltd.

OptimizeRx Corporation

8.29
-0.4600-5.26%
Post-market: 8.900.6093+7.35%19:32 EST
Volume:379.26K
Turnover:3.16M
Market Cap:154.53M
PE:4.51K
High:8.84
Open:8.62
Low:8.16
Close:8.75
52wk High:22.25
52wk Low:3.99
Shares:18.64M
Float Shares:14.32M
Volume Ratio:0.69
T/O Rate:2.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.0018
EPS(LYR):-1.0993
ROE:0.03%
ROA:2.52%
PB:1.26
PE(LYR):-7.54

Loading ...

OptimizeRx Corporation to Announce Fourth Quarter and Full Year 2025 Financial Results

Reuters
·
Feb 05

The 13% return this week takes OptimizeRx's (NASDAQ:OPRX) shareholders one-year gains to 156%

Simply Wall St.
·
Jan 08

BRIEF-Optimizerx And Experian Collaborate To Improve Privacy-Safe Identity Resolution In Healthcare Marketing

Reuters
·
Jan 07

OptimizeRx Partners with Experian to Enhance Privacy-Safe Healthcare Marketing

Reuters
·
Jan 07

OptimizeRx and Experian Collaborate to Improve Privacy-Safe Identity Resolution in Healthcare Marketing

THOMSON REUTERS
·
Jan 07

OptimizeRx Chief Finance & Strategy Officer Edward Stelmakh Reports Disposal of Common Shares

Reuters
·
Dec 22, 2025

OptimizeRx Secures Exclusive Multi-Year Partnerships to Expand Point-of-Care Network

Reuters
·
Dec 17, 2025

Halozyme Therapeutics Elects Jim Lang to Board of Directors

Reuters
·
Dec 09, 2025

OPTIMIZERx Q3 Revenue USD 26.1 Million Vs. IBES Estimate USD 23.8 Million

Reuters
·
Nov 20, 2025

OptimizeRx Unveils Presentation Showcasing Technology Solutions for Patient Engagement and Pharma Connectivity

Reuters
·
Nov 19, 2025

Stifel Nicolaus Remains a Buy on OptimizeRx (OPRX)

TIPRANKS
·
Nov 19, 2025

OptimizeRx Is Maintained at Equal-Weight by Stephens & Co.

Dow Jones
·
Nov 17, 2025

OptimizeRx Corporation Files Initial Beneficial Ownership Statement for Brendan W. Merrell, Chief Operating Officer

Reuters
·
Nov 10, 2025

OptimizeRx Q3 2025 Earnings Call Summary and Q&A Highlights: Strategic Partnerships and Predictable Revenue Model

Earnings Call
·
Nov 10, 2025

OptimizeRx (OPRX) Q3 2025 Earnings Call Transcript

Motley Fool Transcribing
·
Nov 10, 2025

OptimizeRx Down Over 17%, on Pace for Largest Percent Decrease Since November 2024 -- Data Talk

Dow Jones
·
Nov 08, 2025

OptimizeRx Is Maintained at Market Outperform by Citizens

Dow Jones
·
Nov 07, 2025

OptimizeRx reports Q3 revenue of $26.1 million, up 22% year-over-year

Reuters
·
Nov 07, 2025

BRIEF-OPTIMIZERx Q3 Revenue USD 26.1 Million Vs. IBES Estimate USD 23.8 Million

Reuters
·
Nov 07, 2025

OptimizeRx Q3 Gross Profit USD 17.5 Million

THOMSON REUTERS
·
Nov 07, 2025